Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
Department of Orthopedic Surgery, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
Langenbecks Arch Surg. 2021 Aug;406(5):1635-1642. doi: 10.1007/s00423-020-02062-z. Epub 2021 Jan 15.
Retroperitoneal sarcoma (RPS) is a rare tumor with a poor prognosis and is often undetected until it is significantly enlarged. While surgical resection remains the primary treatment, there is little research on its benefits, especially that concerning the reoperation of recurrent disease. This study investigated the impact of surgical procedures, especially reoperation of recurrent RPS, on prognosis.
This retrospective study included 51 patients who underwent radical resection surgery (R0 status) for primary or recurrent RPS without distant metastasis. Patient outcomes and prognosis were defined in terms of the clinicopathologic factors and surgical techniques performed.
In all cases, the 5-year disease-free survival (DFS) rate was 28.2%, 5-year overall survival rate was 89.9%, and 5-year no residual liposarcoma rate was 54.3% after operation and re-reoperation. There was a statistically significant difference between the 5-year DFS rate and 5-year no residual liposarcoma rate due to frequent re-reoperation (p = 0.011). On univariate analysis of primary and recurrent lesions, the histological type and the number of organs involved were identified as statistically significant prognostic factors. Patients with well-differentiated liposarcomas had a statistically better prognosis than those with other cancer types (primary RPS, p = 0.028; recurrence, p = 0.024).
Aggressive and frequent resection of recurrent RPS with combined resection of adjacent organs contributes to long-term survival. The establishment of a surgical strategy for RPS will require a prospective study.
腹膜后肉瘤(RPS)是一种罕见的肿瘤,预后较差,通常在明显增大后才被发现。虽然手术切除仍然是主要的治疗方法,但关于其益处的研究很少,特别是关于复发性疾病的再次手术。本研究调查了手术程序,特别是复发性 RPS 的再次手术,对预后的影响。
本回顾性研究纳入了 51 例接受根治性切除术(R0 状态)治疗的原发性或复发性 RPS 患者,无远处转移。根据临床病理因素和手术技术,定义患者的结局和预后。
所有患者的 5 年无病生存率(DFS)为 28.2%,5 年总生存率为 89.9%,术后和再次手术后 5 年无残留脂肪肉瘤率为 54.3%。由于频繁的再次手术,5 年 DFS 率和 5 年无残留脂肪肉瘤率之间存在统计学差异(p=0.011)。对原发性和复发性病变进行单因素分析,组织学类型和受累器官数量被确定为统计学上显著的预后因素。分化良好的脂肪肉瘤患者的预后明显优于其他癌症类型(原发性 RPS,p=0.028;复发,p=0.024)。
积极频繁地切除复发性 RPS,并联合切除相邻器官,有助于长期生存。需要进行前瞻性研究来建立 RPS 的手术策略。